Nucleos(t)ide analogue treatment in hepatitis B: to stop or not to stop?

Expert Review of Anti-infective Therapy 2026

View at publisher
Authors: Μargarita Papatheodoridi, G. Papatheodoridis
DOI: 10.1080/14787210.2025.2611311
Cited by: 2
References: 52

Abstract

INTRODUCTION: Monotherapy with a nucleos(t)ide analogue (NA), namely entecavir and tenofovir, represents the mainstay of hepatitis B virus (HBV) treatment, which achieves potent viral suppression and subsequently improved major outcomes, but it rarely leads to functional cure (i.e. 10-year cumulative rate of

Fields of Study & Subjects

Hepatitis B Virus Studies Hepatitis C virus research Hepatitis Viruses Studies and Epidemiology

Publication details

Journal / source
Expert Review of Anti-infective Therapy
Publisher
Informa UK Limited
Volume
24
Issue
1
Pages
113–120
Publication date
2 January 2026
Language
EN